Symbols / JAZZ Stock $203.98 +1.37% Jazz Pharmaceuticals plc

Healthcare • Biotechnology • Ireland • NMS
JAZZ (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Ms. Renee D. Gala
Exch · Country NMS · Ireland
Market Cap 12.80B
Enterprise Value 15.54B
Income -356.15M
Sales 4.27B
FCF (ttm) 1.35B
Book/sh 70.30
Cash/sh 39.67
Employees 2,890
Insider 10d —
IPO Jun 01, 2007
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 8.10
PEG 0.64
P/S 3.00
P/B 2.90
P/C —
EV/EBITDA 9.07
EV/Sales 3.64
Quick Ratio 1.46
Current Ratio 1.86
Debt/Eq 125.67
LT Debt/Eq —
EPS (ttm) -5.83
EPS next Y 25.19
EPS Growth 3.20%
Revenue Growth 10.10%
EPS Gr Q/Q 6.50%
Rev Gr Q/Q —
Earnings (next) 2026-05-05
Earnings (prior) 2023-05-10
ROA 5.38%
ROE -8.47%
ROIC —
Gross Margin 91.67%
Oper. Margin 27.06%
Profit Margin -8.35%
Shs Outstand 62.74M
Shs Float 59.61M
Insider Own 3.01%
Instit Own 102.74%
Short Float 9.82%
Short Ratio 6.14
Short Interest 5.24M
52W High 207.48
vs 52W High -1.69%
52W Low 97.50
vs 52W Low 109.21%
Beta 0.23
Impl. Vol. 1.56%
Rel Volume 0.60
Avg Volume 956.22K
Volume 575.17K
Target (mean) $225.53
Tgt Median $226.00
Tgt Low $188.00
Tgt High $275.00
# Analysts 17
Recom Buy
Prev Close $201.22
Price $203.98
Change 1.37%
About

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$225.53
Mean price target
2. Current target
$203.98
Latest analyst target
3. DCF / Fair value
$388.64
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$203.98
Low
$188.00
High
$275.00
Mean
$225.53

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-22 main Leerink Partners Outperform → Outperform $225
2026-04-20 main Barclays Overweight → Overweight $225
2026-03-19 main Piper Sandler Overweight → Overweight $232
2026-02-27 init Barclays — → Overweight $224
2026-02-25 main RBC Capital Outperform → Outperform $195
2026-02-25 main Morgan Stanley Overweight → Overweight $226
2026-02-25 main Wells Fargo Overweight → Overweight $250
2026-02-25 main B of A Securities Buy → Buy $275
2026-01-12 main Truist Securities Buy → Buy $230
2026-01-12 main Needham Buy → Buy $235
2025-12-10 reit Piper Sandler Overweight → Overweight $219
2025-11-24 down UBS Buy → Neutral $188
2025-11-18 main Wells Fargo Overweight → Overweight $235
2025-11-18 main Baird Outperform → Outperform $209
2025-11-18 main B of A Securities Buy → Buy $247
2025-11-17 main RBC Capital Outperform → Outperform $194
2025-11-17 main Morgan Stanley Overweight → Overweight $205
2025-11-06 main RBC Capital Outperform → Outperform $155
2025-10-27 main JP Morgan Overweight → Overweight $199
2025-10-20 main Morgan Stanley Overweight → Overweight $180
News
RSS: Latest JAZZ news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-01 COZADD BRUCE C Director — 6,000 $190.22 $1,143,010
2026-03-09 CARR PATRICIA Officer — 1,287 $182.94 $235,444
2026-03-03 COZADD BRUCE C Director — 6,000 $186.09 $1,118,613
2026-02-27 CARR PATRICIA Officer — 2,370 $190.91 $456,466
2026-02-27 RIEDEL NORBERT G Director — 3,415 $192.00 $655,680
2026-02-27 RIEDEL NORBERT G Director — 3,415 $138.08 $471,543
2026-02-26 CARR PATRICIA Officer — 2,223 $0.00 $0
2026-02-26 PEARCE SAMANTHA Officer — 9,782 $0.00 $0
2026-02-26 HENDERSON MARY ELIZABETH Officer — 4,447 $0.00 $0
2026-02-26 HENDERSON MARY ELIZABETH Officer — 5,343 $194.49 $1,039,134
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
4,267.59
+4.88%
4,068.95
+6.12%
3,834.20
+4.78%
3,659.37
Operating Revenue
4,267.59
+4.88%
4,068.95
+6.12%
3,834.20
+4.78%
3,659.37
Cost Of Revenue
503.30
+12.92%
445.71
+2.33%
435.58
-19.41%
540.52
Reconciled Cost Of Revenue
461.66
+11.79%
412.96
+1.92%
405.17
-20.59%
510.21
Gross Profit
3,764.29
+3.89%
3,623.24
+6.61%
3,398.63
+8.97%
3,118.86
Operating Expense
3,246.67
+12.09%
2,896.61
+3.41%
2,801.05
+7.46%
2,606.59
Research And Development
782.74
-11.46%
884.00
+4.04%
849.66
+43.90%
590.45
Selling General And Administration
1,809.27
+30.61%
1,385.29
+3.14%
1,343.11
-5.21%
1,416.97
Total Expenses
3,749.96
+12.20%
3,342.32
+3.27%
3,236.62
+2.84%
3,147.11
Operating Income
517.62
-28.76%
726.63
+21.60%
597.58
+16.65%
512.27
Total Operating Income As Reported
-430.24
-160.04%
716.63
+23.86%
578.58
+982.95%
-65.53
EBITDA
263.49
-80.75%
1,368.52
+11.62%
1,226.06
+124.99%
544.93
Normalized EBITDA
1,213.92
-12.46%
1,386.70
+12.17%
1,236.28
+8.28%
1,141.74
Reconciled Depreciation
696.30
+5.49%
660.07
+3.35%
638.70
+1.47%
629.47
EBIT
-432.81
-161.09%
708.45
+20.61%
587.37
+794.76%
-84.54
Total Unusual Items
-950.43
-5127.31%
-18.18
-78.03%
-10.21
+98.29%
-596.81
Total Unusual Items Excluding Goodwill
-950.43
-5127.31%
-18.18
-78.03%
-10.21
+98.29%
-596.81
Special Income Charges
-947.86
-9378.62%
-10.00
+47.37%
-19.00
+96.71%
-577.80
Other Special Charges
947.86
+9378.62%
10.00
-47.37%
19.00
-95.72%
444.15
Impairment Of Capital Assets
—
0.00
0.00
-100.00%
133.65
Net Income
-356.15
-163.58%
560.12
+35.02%
414.83
+285.14%
-224.06
Pretax Income
-627.86
-233.49%
470.35
+57.87%
297.93
+179.92%
-372.78
Net Non Operating Interest Income Expense
-195.05
+18.08%
-238.10
+17.74%
-289.44
-0.41%
-288.24
Interest Expense Non Operating
195.05
-18.08%
238.10
-17.74%
289.44
+0.41%
288.24
Net Interest Income
-195.05
+18.08%
-238.10
+17.74%
-289.44
-0.41%
-288.24
Interest Expense
195.05
-18.08%
238.10
-17.74%
289.44
+0.41%
288.24
Other Income Expense
-950.43
-5127.31%
-18.18
-78.03%
-10.21
+98.29%
-596.81
Gain On Sale Of Security
-2.57
+68.61%
-8.18
-193.11%
8.79
+146.21%
-19.01
Tax Provision
-272.44
-197.98%
-91.43
+23.75%
-119.91
+24.41%
-158.65
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-199.59
-5127.31%
-3.82
-78.03%
-2.14
+98.29%
-125.33
Net Income Including Noncontrolling Interests
-356.15
-163.58%
560.12
+35.02%
414.83
+285.14%
-224.06
Net Income From Continuing Operation Net Minority Interest
-356.15
-163.58%
560.12
+35.02%
414.83
+285.14%
-224.06
Net Income From Continuing And Discontinued Operation
-356.15
-163.58%
560.12
+35.02%
414.83
+285.14%
-224.06
Net Income Continuous Operations
-356.15
-163.58%
560.12
+35.02%
414.83
+285.14%
-224.06
Normalized Income
394.69
-31.30%
574.48
+35.84%
422.90
+70.92%
247.42
Net Income Common Stockholders
-356.15
-163.58%
560.12
+35.02%
414.83
+285.14%
-224.06
Diluted EPS
-5.84
-167.51%
8.65
+41.80%
6.10
+270.39%
-3.58
Basic EPS
-5.84
-164.46%
9.06
+38.32%
6.55
+282.96%
-3.58
Basic Average Shares
60.98
-1.39%
61.84
-2.30%
63.29
+1.20%
62.54
Diluted Average Shares
60.98
-7.61%
66.01
-8.41%
72.07
+15.23%
62.54
Diluted NI Availto Com Stockholders
-356.15
-162.39%
570.88
+29.83%
439.71
+296.25%
-224.06
Average Dilution Earnings
0.00
-100.00%
10.76
-56.74%
24.88
0.00
Amortization
654.66
+4.36%
627.31
+3.13%
608.28
+1.52%
599.17
Amortization Of Intangibles Income Statement
654.66
+4.36%
627.31
+3.13%
608.28
+1.52%
599.17
Depreciation Amortization Depletion Income Statement
654.66
+4.36%
627.31
+3.13%
608.28
+1.52%
599.17
Depreciation And Amortization In Income Statement
654.66
+4.36%
627.31
+3.13%
608.28
+1.52%
599.17
Earnings From Equity Interest Net Of Tax
-0.73
+55.90%
-1.66
+44.83%
-3.01
+69.67%
-9.92
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
11,659.34
-2.94%
12,012.26
+5.43%
11,393.36
+5.15%
10,835.25
Current Assets
4,166.04
-10.00%
4,629.03
+34.74%
3,435.43
+31.82%
2,606.14
Cash Cash Equivalents And Short Term Investments
2,441.90
-18.41%
2,992.86
+84.03%
1,626.31
+84.50%
881.48
Cash And Cash Equivalents
1,391.90
-42.31%
2,412.86
+60.18%
1,506.31
+70.88%
881.48
Cash Equivalents
709.15
-51.56%
1,463.97
+37.00%
1,068.59
+95.19%
547.46
Cash Financial
682.75
-28.05%
948.89
+116.78%
437.72
+31.05%
334.02
Other Short Term Investments
1,050.00
+81.03%
580.00
+383.33%
120.00
0.00
Receivables
830.75
+15.90%
716.76
+1.55%
705.79
+8.33%
651.49
Accounts Receivable
830.75
+15.90%
716.76
+1.55%
705.79
+8.33%
651.49
Gross Accounts Receivable
848.04
+13.15%
749.46
+3.10%
726.93
+8.60%
669.34
Allowance For Doubtful Accounts Receivable
-17.29
+47.10%
-32.69
-54.67%
-21.14
-18.46%
-17.84
Inventory
416.96
-13.21%
480.44
-19.53%
597.04
-16.39%
714.06
Raw Materials
21.96
+8.94%
20.16
-21.23%
25.59
+23.14%
20.79
Work In Process
253.35
-18.73%
311.75
-27.79%
431.73
-16.60%
517.67
Finished Goods
141.65
-4.63%
148.53
+6.31%
139.71
-20.44%
175.60
Prepaid Assets
152.48
-14.05%
177.41
-4.35%
185.48
+101.80%
91.91
Current Deferred Assets
—
—
171.51
-2.58%
176.06
Other Current Assets
323.95
+23.86%
261.54
-18.47%
320.81
+252.02%
91.14
Total Non Current Assets
7,493.30
+1.49%
7,383.23
-7.22%
7,957.93
-3.30%
8,229.11
Net PPE
258.74
+13.98%
227.00
-3.40%
234.99
-22.03%
301.38
Gross PPE
437.29
+12.43%
388.95
+5.60%
368.34
-9.95%
409.02
Accumulated Depreciation
-178.55
-10.25%
-161.96
-21.45%
-133.35
-23.88%
-107.65
Properties
0.00
0.00
0.00
0.00
Land And Improvements
72.23
+0.46%
71.90
+1.40%
70.91
+2.87%
68.94
Machinery Furniture Equipment
192.98
+21.54%
158.77
+8.97%
145.70
+8.25%
134.60
Construction In Progress
49.63
+43.90%
34.49
+84.84%
18.66
-72.31%
67.39
Other Properties
58.88
+9.89%
53.58
-18.00%
65.34
-10.89%
73.33
Leases
63.57
-9.45%
70.20
+3.66%
67.72
+4.55%
64.78
Goodwill And Other Intangible Assets
6,258.85
-3.29%
6,472.02
-9.75%
7,171.17
-4.22%
7,487.10
Goodwill
1,829.34
+6.58%
1,716.32
-2.10%
1,753.13
+3.57%
1,692.66
Other Intangible Assets
4,429.51
-6.86%
4,755.69
-12.22%
5,418.04
-6.50%
5,794.44
Non Current Deferred Assets
876.68
+53.88%
569.73
+17.64%
484.31
+25.63%
385.50
Non Current Deferred Taxes Assets
869.13
+55.13%
560.25
+17.25%
477.83
+27.00%
376.25
Other Non Current Assets
99.03
-13.50%
114.48
+69.69%
67.46
+22.35%
55.14
Total Liabilities Net Minority Interest
7,340.76
-7.30%
7,918.50
+3.42%
7,656.36
-1.20%
7,749.52
Current Liabilities
2,242.52
+115.92%
1,038.57
-32.42%
1,536.69
+64.67%
933.19
Payables And Accrued Expenses
951.91
+18.54%
803.03
+4.29%
769.97
+7.48%
716.38
Payables
178.45
+84.68%
96.63
-29.89%
137.82
+39.96%
98.47
Accounts Payable
122.06
+56.75%
77.87
-24.22%
102.75
+13.21%
90.76
Current Accrued Expenses
773.47
+9.49%
706.41
+11.75%
632.14
+2.30%
617.91
Pensionand Other Post Retirement Benefit Plans Current
215.35
+40.63%
153.13
+26.34%
121.21
-15.38%
143.24
Total Tax Payable
56.39
+200.62%
18.76
-46.52%
35.07
+354.50%
7.72
Income Tax Payable
56.39
+200.62%
18.76
-46.52%
35.07
+354.50%
7.72
Current Debt And Capital Lease Obligation
1,044.62
+2181.88%
45.78
-92.67%
624.40
+1230.27%
46.94
Current Debt
1,029.90
+3222.27%
31.00
-94.88%
604.95
+1851.46%
31.00
Other Current Borrowings
1,029.90
+3222.27%
31.00
-94.88%
604.95
+1851.46%
31.00
Current Capital Lease Obligation
14.72
-0.42%
14.78
-24.00%
19.45
+22.02%
15.94
Current Deferred Liabilities
—
—
0.00
-100.00%
0.46
Current Deferred Revenue
—
—
0.00
-100.00%
0.46
Other Current Liabilities
4.22
-58.57%
10.20
+1397.50%
0.68
—
Total Non Current Liabilities Net Minority Interest
5,098.23
-25.90%
6,879.93
+12.42%
6,119.67
-10.22%
6,816.33
Long Term Debt And Capital Lease Obligation
4,379.25
-28.40%
6,116.58
+18.37%
5,167.21
-10.37%
5,765.18
Long Term Debt
4,328.35
-28.78%
6,077.64
+18.98%
5,107.99
-10.28%
5,693.34
Long Term Capital Lease Obligation
50.89
+30.70%
38.94
-34.25%
59.23
-17.56%
71.84
Non Current Deferred Liabilities
594.47
-12.16%
676.74
-20.17%
847.71
-10.23%
944.34
Non Current Deferred Revenue
—
—
—
0.00
Non Current Deferred Taxes Liabilities
594.47
-12.16%
676.74
-20.17%
847.71
-10.23%
944.34
Other Non Current Liabilities
124.52
+43.76%
86.61
-17.31%
104.75
-1.93%
106.81
Stockholders Equity
4,318.58
+5.49%
4,093.76
+9.55%
3,737.00
+21.11%
3,085.73
Common Stock Equity
4,318.58
+5.49%
4,093.76
+9.55%
3,737.00
+21.11%
3,085.73
Capital Stock
0.06
+0.00%
0.06
+0.00%
0.06
+0.00%
0.06
Common Stock
0.06
+0.00%
0.06
+0.00%
0.06
+0.00%
0.06
Share Issued
61.44
+1.33%
60.63
-2.61%
62.26
-1.52%
63.21
Ordinary Shares Number
61.44
+1.33%
60.63
-2.61%
62.26
-1.52%
63.21
Additional Paid In Capital
4,240.94
+8.35%
3,914.01
+5.77%
3,700.43
+6.41%
3,477.60
Retained Earnings
646.18
-42.68%
1,127.35
+28.30%
878.66
+19.78%
733.59
Gains Losses Not Affecting Retained Earnings
-568.60
+40.00%
-947.67
-12.53%
-842.15
+25.18%
-1,125.51
Other Equity Adjustments
-568.60
+40.00%
-947.67
-12.53%
-842.15
+25.18%
-1,125.51
Total Equity Gross Minority Interest
4,318.58
+5.49%
4,093.76
+9.55%
3,737.00
+21.11%
3,085.73
Total Capitalization
8,646.94
-14.99%
10,171.40
+15.00%
8,844.99
+0.75%
8,779.08
Working Capital
1,923.52
-46.43%
3,590.45
+89.10%
1,898.74
+13.50%
1,672.95
Invested Capital
9,676.84
-5.15%
10,202.40
+7.96%
9,449.94
+7.26%
8,810.08
Total Debt
5,423.87
-11.98%
6,162.36
+6.40%
5,791.61
-0.35%
5,812.12
Net Debt
3,966.36
+7.32%
3,695.78
-12.14%
4,206.63
-13.14%
4,842.86
Capital Lease Obligations
65.61
+22.14%
53.72
-31.72%
78.67
-10.37%
87.78
Net Tangible Assets
-1,940.27
+18.42%
-2,378.26
+30.75%
-3,434.17
+21.97%
-4,401.36
Tangible Book Value
-1,940.27
+18.42%
-2,378.26
+30.75%
-3,434.17
+21.97%
-4,401.36
Current Provisions
26.41
-0.06%
26.43
+29.33%
20.43
-21.90%
26.16
Interest Payable
40.67
-2.30%
41.63
+14.22%
36.44
+2.33%
35.61
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
1,355.77
-2.88%
1,395.91
+27.83%
1,092.01
-14.15%
1,271.98
Cash Flow From Continuing Operating Activities
1,355.77
-2.88%
1,395.91
+27.83%
1,092.01
-14.15%
1,271.98
Net Income From Continuing Operations
-356.15
-163.58%
560.12
+35.02%
414.83
+285.14%
-224.06
Depreciation Amortization Depletion
696.30
+5.49%
660.07
+3.35%
638.70
+1.47%
629.47
Depreciation
41.64
+27.12%
32.75
+7.70%
30.41
+0.36%
30.30
Amortization Cash Flow
654.66
+4.36%
627.31
+3.13%
608.28
+1.52%
599.17
Depreciation And Amortization
696.30
+5.49%
660.07
+3.35%
638.70
+1.47%
629.47
Amortization Of Intangibles
654.66
+4.36%
627.31
+3.13%
608.28
+1.52%
599.17
Other Non Cash Items
1,131.45
+511.71%
184.97
-9.41%
204.17
-72.45%
741.03
Stock Based Compensation
291.13
+17.37%
248.04
+9.35%
226.84
+2.18%
222.00
Provisionand Write Offof Assets
19.11
-31.16%
27.76
+149.78%
11.11
-23.55%
14.54
Asset Impairment Charge
0.00
0.00
-100.00%
61.01
-54.35%
133.65
Deferred Tax
-444.97
-113.59%
-208.33
+19.94%
-260.22
+10.96%
-292.25
Deferred Income Tax
-444.97
-113.59%
-208.33
+19.94%
-260.22
+10.96%
-292.25
Operating Gains Losses
—
—
—
37.70
Change In Working Capital
18.90
+124.63%
-76.72
+62.47%
-204.44
-2164.00%
9.90
Change In Receivables
-106.28
-403.33%
-21.11
+59.30%
-51.88
+42.44%
-90.14
Changes In Account Receivables
-106.28
-403.33%
-21.11
+59.30%
-51.88
+42.44%
-90.14
Change In Inventory
-86.04
-88.93%
-45.54
-239.36%
-13.42
+72.97%
-49.64
Change In Prepaid Assets
29.03
+231.15%
-22.14
+82.59%
-127.11
-455.19%
35.79
Change In Payables And Accrued Expense
154.17
+200.27%
51.34
+343.46%
11.58
-92.44%
153.07
Change In Accrued Expense
77.10
-10.52%
86.16
+470.66%
-23.25
-114.00%
165.99
Change In Payable
77.08
+321.38%
-34.81
-199.98%
34.82
+369.59%
-12.92
Change In Account Payable
39.85
+298.53%
-20.07
-309.03%
9.60
+185.55%
-11.22
Change In Other Working Capital
—
—
-0.46
+77.88%
-2.09
Change In Other Current Assets
—
-32.71
-3394.55%
-0.94
+89.90%
-9.27
Change In Other Current Liabilities
28.02
+171.34%
-39.27
-66.41%
-23.60
+15.17%
-27.82
Investing Cash Flow
-1,509.91
-197.11%
-508.19
-211.66%
-163.06
+63.46%
-446.23
Cash Flow From Continuing Investing Activities
-1,509.91
-197.11%
-508.19
-211.66%
-163.06
+63.46%
-446.23
Net PPE Purchase And Sale
-58.75
-54.33%
-38.07
-58.88%
-23.96
+17.50%
-29.05
Purchase Of PPE
-58.75
-54.33%
-38.07
-58.88%
-23.96
+17.50%
-29.05
Capital Expenditure
-209.75
-336.35%
-48.07
-11.89%
-42.96
+91.38%
-498.19
Net Investment Purchase And Sale
-470.27
-2.21%
-460.12
-283.12%
-120.10
-11492.66%
-1.04
Purchase Of Investment
-1,830.28
-40.24%
-1,305.12
-234.56%
-390.10
-539.13%
-61.04
Sale Of Investment
1,360.00
+60.95%
845.00
+212.96%
270.00
+350.00%
60.00
Net Business Purchase And Sale
-858.05
0.00
0.00
-100.00%
53.00
Purchase Of Business
-858.05
0.00
0.00
0.00
Gain Loss On Sale Of Business
—
0.00
0.00
-100.00%
37.70
Net Intangibles Purchase And Sale
-151.00
-1410.00%
-10.00
+47.37%
-19.00
+95.95%
-469.15
Purchase Of Intangibles
-151.00
-1410.00%
-10.00
+47.37%
-19.00
+95.95%
-469.15
Net Other Investing Changes
28.17
—
—
—
Financing Cash Flow
-873.38
-4357.07%
20.52
+106.72%
-305.25
+42.35%
-529.49
Cash Flow From Continuing Financing Activities
-873.38
-4357.07%
20.52
+106.72%
-305.25
+42.35%
-529.49
Net Issuance Payments Of Debt
-781.00
-308.40%
374.77
+1308.93%
-31.00
+94.67%
-582.01
Issuance Of Debt
0.00
-100.00%
980.77
0.00
0.00
Repayment Of Debt
-781.00
-28.88%
-606.00
-1854.84%
-31.00
+94.67%
-582.01
Long Term Debt Issuance
0.00
-100.00%
980.77
0.00
0.00
Long Term Debt Payments
-781.00
-28.88%
-606.00
-1854.84%
-31.00
+94.67%
-582.01
Net Long Term Debt Issuance
-781.00
-308.40%
374.77
+1308.93%
-31.00
+94.67%
-582.01
Short Term Debt Issuance
—
—
—
0.00
Short Term Debt Payments
—
—
—
0.00
Net Short Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
-125.02
+59.86%
-311.43
-15.45%
-269.76
-499457.41%
-0.05
Common Stock Payments
-125.02
+59.86%
-311.43
-15.45%
-269.76
-499457.41%
-0.05
Repurchase Of Capital Stock
-125.02
+59.86%
-311.43
-15.45%
-269.76
-499457.41%
-0.05
Proceeds From Stock Option Exercised
107.86
+422.41%
20.65
-55.56%
46.46
-52.60%
98.02
Net Other Financing Charges
-75.22
-18.51%
-63.47
-24.57%
-50.95
-12.12%
-45.44
Changes In Cash
-1,027.52
-213.13%
908.23
+45.62%
623.69
+110.52%
296.26
Effect Of Exchange Rate Changes
6.55
+491.34%
-1.68
-247.32%
1.14
+118.27%
-6.22
Beginning Cash Position
2,412.86
+60.18%
1,506.31
+70.88%
881.48
+49.04%
591.45
End Cash Position
1,391.90
-42.31%
2,412.86
+60.18%
1,506.31
+70.88%
881.48
Free Cash Flow
1,146.02
-14.97%
1,347.84
+28.48%
1,049.05
+35.57%
773.78
Interest Paid Supplemental Data
248.55
-21.05%
314.82
-5.49%
333.11
+23.07%
270.67
Income Tax Paid Supplemental Data
121.81
+6.01%
114.91
-35.40%
177.88
+87.87%
94.68
Change In Income Tax Payable
37.22
+352.50%
-14.74
-158.45%
25.22
+1590.54%
-1.69
Change In Tax Payable
37.22
+352.50%
-14.74
-158.45%
25.22
+1590.54%
-1.69
Dividend Received CFO
—
—
—
0.00
Sale Of Business
—
0.00
0.00
-100.00%
53.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category